Efficacy and tolerance of Flunixin (SCH 14714) in the treatment of postoperative pain, with observations on the methodology of postoperative pain studies.
A new anti-inflammatory, antipyretic and analgesic drug 2(2'-methyl-3'-trifluoromethylanilino)-nicotinic acid (Flunixin, Sch 14714) was compared with aspirin and a placebo in a double-blind study of pain after four different types of operation. Sch 14714 proved to be superior to the two other drugs after herniorraphy and venous surgery of the leg. The frequency of adverse effects after this drug was, at most. 1.2% which did not differ from the side-effect rates of aspirin or placebo. The second and third days after operation yielded a very high rate of optimal pain relief scores resulting in poor discrimination. Thus cross-over studies seem to be superfluous in the study of pain-relieving drugs in the period following surgery. The patients' rather low demand of analgesic drugs indicated that more stringent enrollment criteria should be adhered to. It was also shown that radical venous surgery constituted a good model for pain studies.
D000814:Aniline Compounds / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003002:Clonixin / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008297:Male; D009539:Nicotinic Acids / Q000627:therapeutic use*; D010149:Postoperative Pain / Q000188:drug therapy*; D012107:Research Design; D013997:Time Factors
D000814:Aniline Compounds; D000894:Anti-Inflammatory Agents, Non-Steroidal; D009539:Nicotinic Acids; C014557:flunixin; D001241:Aspirin; D003002:Clonixin